Dr Reddy's Laboratories Ltd
F:RDDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dr Reddy's Laboratories Ltd
F:RDDA
|
IN |
|
A
|
Alaska Air Group Inc
F:ALK
|
US |
|
S
|
Salesforce Inc
F:FOO
|
US |
|
S
|
Sumitomo Realty & Development Co Ltd
XMUN:RL2
|
JP |
Wall St Price Targets
RDDA Price Targets Summary
Dr Reddy's Laboratories Ltd
According to Wall Street analysts, the average 1-year price target for RDDA is 12.3 EUR with a low forecast of 9.45 EUR and a high forecast of 16.53 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RDDA's stock price target?
Price Target
12.3
EUR
According to Wall Street analysts, the average 1-year price target for RDDA is 12.3 EUR with a low forecast of 9.45 EUR and a high forecast of 16.53 EUR.
What is the Revenue forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 4 years is 8%.
What is the Gross Profit forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 4 years is 3%.
What is the Operating Income forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
1%
Over the last 13 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 4 years is 1%.
What is the Pre-Tax Income forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
-1%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is -1%.
What is the Net Income forecast for Dr Reddy's Laboratories Ltd?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Net Income has been 12%. The projected CAGR for the next 4 years is 2%.
